If you're still compounding tirzepatide or semaglutide without meeting patient-specific exceptions, compliance is now mandatory. The enforcement discretion period for both drugs has ended.

Conclusions Once-weekly cagrilintide–semaglutide (at a dose of 2.4 mg each) resulted in a significantly lower body weight than placebo in adults with obesity and type 2 diabetes.

The sub-analysis builds on results previously published in The Lancet, demonstrating that semaglutide significantly improved walking outcomes in people with PAD and diabetes, enhanced quality of ...